Arcellx, Inc.
anito-cel
relapsed or refractory multiple myeloma
Countdown
169days
FDA decision · Dec 23, 2026
What's at stake
The FDA's approval decision on anito-cel for relapsed or refractory multiple myeloma is due Dec 23, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“with an anticipated Prescription Drug User Fee Act (PDUFA) action date of December 23, 2026”